Cyclerion Therapeutics, Inc. Income Statement
CYCN|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$2M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$5M
FY2025
Net Income
-$4M
FY2025
Cyclerion Therapeutics, Inc. reported $2M in revenue and $4M in net loss for FY2025. Revenue has declined at a 12.1% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $0 | $297.0K | $297.0K | $2.3M | $4.5M | $4.5M |
| SG&A Expense | $6.1M | $8.1M | $12.9M | $12.9M | $28.8M | $34.4M | $27.5M |
| R&D Expense | $959.0K | $1.5M | $6.0M | $6.0M | $56.4M | $95.1M | $87.7M |
| Operating Income | -$5.0M | -$13.0M | -$18.5M | -$18.5M | -$81.3M | -$125.0M | -$115.3M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | - | $0 |
| Net Income | -$3.5M | -$5.3M | -$44.1M | -$44.1M | -$77.8M | -$123.0M | -$115.3M |
| EPS (Basic) | -$1.21 | -$2.25 | -$20.28 | -$1.32 | - | - | - |
| EPS (Diluted) | -$1.21 | -$2.25 | -$20.28 | -$1.32 | -$2.56 | -$4.49 | -$4.21 |
| Shares Outstanding | 2.5M | 2.5M | 2.2M | 43.4M | 30.4M | 27.6M | 0 |
| Operating Margin | -239.8% | - | -6242.4% | -6242.4% | -3539.4% | -2774.3% | -2557.2% |
| Profit Margin | -170.1% | - | -14841.1% | -14841.1% | -3388.6% | -2729.3% | -2557.2% |